原发性胆汁性胆管炎合并肝血管肉瘤1例报告

赵嘉敏; 陈知远; 丁成亮; 袁莉莉; 钱晶晶; 徐春阳; 左凌云

doi:10.3969/j.issn.1001-5256.2021.10.031

原发性胆汁性胆管炎合并肝血管肉瘤1例报告

DOI: 10.3969/j.issn.1001-5256.2021.10.031

1.
南京中医药大学医学院·整合医学院, 南京 210046
2a.
南京中医药大学附属南京医院南京市第二医院消化科，南京 210003
2b.
南京中医药大学附属南京医院南京市第二医院放射科，南京 210003
2c.
南京中医药大学附属南京医院南京市第二医院肝脏肿瘤治疗中心介入组，南京 210003

详细信息

通信作者:
左凌云，teajello@163.com

中图分类号: R575
计量
- 文章访问数: 287
- HTML全文浏览量: 86
- PDF下载量: 34
- 被引次数: 0
出版历程
- 收稿日期: 2021-03-04
- 录用日期: 2021-06-16
- 出版日期: 2021-10-20

Primary biliary cholangitis with hepatic angiosarcoma: A case report

1.
School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210046, China
2a.
Department of Gastroenterology, Liver Cancer Treatment Center, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine & Nanjing Second Hospital, Nanjing 210003, China
2b.
Department of Radiology, Liver Cancer Treatment Center, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine & Nanjing Second Hospital, Nanjing 210003, China
2c.
Interventional Group, Liver Cancer Treatment Center, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine & Nanjing Second Hospital, Nanjing 210003, China

摘要

- 原发性胆汁性胆管炎 /
- 血管肉瘤 /
- 肿瘤转移
- Primary Biliary Cholangitis /
- Hemangiosarcoma /
- Neoplasm Metastasis

HTML全文

图 1 全腹部CT平扫+增强检查结果

注：a, 平扫; b, 延迟; c, 增强。

下载: 全尺寸图片幻灯片

图 2 DSA术中情况

注：骨质破坏(箭头处)

下载: 全尺寸图片幻灯片

图 3 腰椎MRI检查结果

注：a、b, HE染色，×100; c、d, CD31染色，×100。

下载: 全尺寸图片幻灯片

图 4 病理学检查结果

下载: 全尺寸图片幻灯片

参考文献(18)

[1]	LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 practice guidance from the american association for the study of liver diseases[J]. Hepatology, 2019, 69(1): 394-419. DOI: 10.1002/hep.30145.
[2]	SYLVESTRE PB, BATTS KP, BURGART LJ, et al. Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history[J]. Liver Transpl, 2003, 9(10): 1086-1093. DOI: 10.1053/jlts.2003.50213.
[3]	YOUNOSSI ZM, BERNSTEIN D, SHIFFMAN ML, et al. Diagnosis and management of primary biliary cholangitis[J]. Am J Gastroenterol, 2019, 114(1): 48-63. DOI: 10.1038/s41395-018-0390-3.
[4]	MOLINA E, HERNANDEZ A. Clinical manifestations of primary hepatic angiosarcoma[J]. Dig Dis Sci, 2003, 48(4): 677-682. DOI: 10.1023/a:1022868221670.
[5]	MANI H, van THIEL DH. Mesenchymal tumors of the liver[J]. Clin Liver Dis, 2001, 5(1): 219-257. DOI: 10.1016/s1089-3261(05)70162-8.
[6]	HUANG NC, WANN SR, CHANG HT, et al. Arsenic, vinyl chloride, viral hepatitis, and hepatic angiosarcoma: A hospital-based study and review of literature in Taiwan[J]. BMC Gastroenterol, 2011, 11: 142. DOI: 10.1186/1471-230X-11-142.
[7]	DUAN XF, LI Q. Primary hepatic angiosarcoma: A retrospective analysis of 6 cases[J]. J Dig Dis, 2012, 13(7): 381-385. DOI: 10.1111/j.1751-2980.2012.00600.x.
[8]	CHAUDHARY P, BHADANA U, SINGH RA, et al. Primary hepatic angiosarcoma[J]. Eur J Surg Oncol, 2015, 41(9): 1137-1143. DOI: 10.1016/j.ejso.2015.04.022.
[9]	ZHU YP, CHEN YM, MATRO E, et al. Primary hepatic angiosarcoma: A report of two cases and literature review[J]. World J Gastroenterol, 2015, 21(19): 6088-6096. DOI: 10.3748/wjg.v21.i19.6088.
[10]	MESIANO S, FERRARA N, JAFFE RB. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization[J]. Am J Pathol, 1998, 153(4): 1249-1256. DOI: 10.1016/S0002-9440(10)65669-6.
[11]	TAMSMA JT, KEIZER HJ, MEINDERS AE. Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited[J]. Ann Oncol, 2001, 12(10): 1353-1357. DOI: 10.1023/a:1012504904713.
[12]	ISHAK KG, SESTERHENN IA, GOODMAN ZD, et al. Epithelioid hemangioendothelioma of the liver: A clinicopathologic and follow-up study of 32 cases[J]. Hum Pathol, 1984, 15(9): 839-852. DOI: 10.1016/s0046-8177(84)80145-8.
[13]	STUDER LL, SELBY DM. Hepatic epithelioid hemangioendothelioma[J]. Arch Pathol Lab Med, 2018, 142(2): 263-267. DOI: 10.5858/arpa.2016-0171-RS.
[14]	OHMOTO K, HIROKAWA M, TAKESUE M, et al. Hepatic angiosarcoma with early central enhancement and arterioportal shunt on dynamic CT[J]. Hepatogastroenterology, 2000, 47(36): 1717-1718. http://europepmc.org/abstract/MED/11149040
[15]	SHIMADA K, NAKAMOTO Y, ISODA H, et al. FDG PET for giant cavernous hemangioma: Important clue to differentiate from a malignant vascular tumor in the liver[J]. Clin Nucl Med, 2010, 35(12): 924-926. DOI: 10.1097/RLU.0b013e3181f9de11.
[16]	TIMARAN CH, GRANDAS OH, BELL JL. Hepatic angiosarcoma: Long-term survival after complete surgical removal[J]. Am Surg, 2000, 66(12): 1153-1157. http://europepmc.org/abstract/MED/11149588
[17]	ZHENG YW, ZHANG XW, ZHANG JL, et al. Primary hepatic angiosarcoma and potential treatment options[J]. J Gastroenterol Hepatol, 2014, 29(5): 906-911. DOI: 10.1111/jgh.12506.
[18]	REGINSTER MA, MAZY V, WALTREGNY D, et al. Hepatic angiosarcoma in a patient with autoimmune hepatitis[J]. Rev Med Liege, 1993, 48(4): 220-223. http://europepmc.org/abstract/MED/8497757